September 16, 2019

Abdi ibrahim aims to increase its efficiency in international markets

Abdi İbrahim, leading corporation of the Turkish pharmaceutical industry, is reported to have engaged in a new organizational structure in tandem with its vision of increase of its efficiency and growth in international markets. As a part of further augmentation of forces of Abdi İbrahim, Köksal Ülgen is appointed and assigned as International Markets Vice President

Continuing its disease healing journey with great successes since 107 years, Abdi İbrahim, as 100 percent local capital corporation of the Turkish pharmaceutical sector, continues to augment its forces in line with its strategies of expansion into new geographies.

Focused on its aim to increase its efficiency in international markets and wishing to make its sustainable growth more agile in the countries it is operating, Abdi İbrahim restructured its Turkey International Markets organization and appointed and assigned Köksal Ülgen as International Markets Vice President.

Köksal Ülgen – International Markets Vice President

Following his undergraduate education in Chemical Engineering department of Istanbul Technical University followed by MBA study program in Koç University, Köksal Ülgen started his career in Eczacıbaşı Pharmaceuticals. Then, he served as Senior Out License Manager in

Eczacıbaşı-Zentiva Pharmaceuticals, and as Business Development Manager in Zentiva Pharmaceuticals and then in Eczacıbaşı-Monrol Nuclear Products, and as Head of Business Development & Licencing in Teva Pharmaceuticals, and as General Manager in Liva Pharmaceuticals and then in Pharmactive Pharmaceuticals. Recently, Ülgen was serving as R&D, Business Development and International Markets Senior Director in Mustafa Nevzat / Amgen Pharmaceutical.